Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Viral Vector Manufacturing Market Through 2029?

The rapid expansion of the viral vector manufacturing market in recent years is significant. The market size is projected to rise from $6.93 billion in 2024 to $8.26 billion in 2025, displaying a compound annual growth rate (CAGR) of 19.1%. The historical growth of this sector can be linked to the expansion of the gene therapies pipeline, successful clinical trials and approvals, enhanced investment in biopharmaceuticals, and a rising incidence of genetic disorders.

The market for viral vector manufacturing is anticipated to experience significant expansion in the forthcoming years. It is projected to escalate to “$17.42 billion in 2029 with a compound annual growth rate (CAGR) of 20.5%.” This anticipated surge during the forecast period can be credited to factors such as rising applicability in oncology, increased global cooperation in gene therapy research, use of viral vectors in vaccine development, ongoing clinical trials, and commercialization. The forecast period is expected to see key trends such as technological advancements in vector manufacture, the rise of next-generation vectors, regulatory adherence and standardization, collaborations and alliances, and worldwide development of manufacturing facilities.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Market Forces Are Driving The Viral Vector Manufacturing Sector In 2025 And Beyond?

The escalation of cancer and infectious disease occurrences is predicted to fuel the expansion of the viral vector manufacturing market in the future. Infectious diseases are typically caused by a virus or its poisonous byproduct and are spread to susceptible hosts through interaction with an infected individual, animal, or object. On the other hand, cancer is a term used to describe a variety of diseases that can manifest in any body organ or tissue when rogue cells multiply uncontrollably, breach their usual boundaries, intrude neighboring organs, and metastasize to other organs. Viral vectors facilitate the production of tumor antigens – proteins present in cancer cells – in order to activate the body’s anticancer immunity. These viral vectors have been used in pre-clinical and clinical experiments as vaccines for a wide range of infectious diseases. For instance, the Australian Institute of Health and Welfare reported in July 2024 that the number of diagnosed cancer cases in Australia escalated from 160,570 in 2022 to 164,694 in 2023 – a significant annual increase indicating the rising cancer prevalence in the country. Additionally, the UK Health Security Agency published data in August 2024 stating that England experienced an almost sevenfold increase in measles cases from 53 in 2022 to 368 in 2023, with the West Midlands and London responsible for 44% and 33% of the reported cases respectively. Consequently, the rising prevalence of cancer and infectious diseases is bolstering the growth of the viral vector manufacturing market.

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

What Upcoming Trends Are Expected To Impact The Viral Vector Manufacturing Market Globally?

The trend of product innovation is increasingly becoming prominent in the viral vector manufacturing market as key companies introduce new products to maintain their market standing. For example, Merck KGaA, a science and technology company based in Germany, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform in August 2022. This company is among the first Contract development and manufacturing organizations and technology inventors to offer a comprehensive viral vector manufacturing suite, which includes AAV, Lentiviral, CDMO, CTO, and process development. This innovative platform allows biopharmaceutical companies to reduce process development time and cost, facilitating a quicker progression to clinical production.

Which Firms Are Considered Leaders In The Viral Vector Manufacturing Market Space?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

What Role Do Regional Policies And Investments Play In Viral Vector Manufacturing Market Expansion?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model